T 1259/22 (Plerixafor to mobilise progenitor/stem cells/GENZYME) of 24.01.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T125922.20240124
- Date of decision
- 24 January 2024
- Case number
- T 1259/22
- Petition for review of
- -
- Application number
- 10184509.7
- IPC class
- A61K 38/19A61K 31/55A61K 31/395A61P 43/00A61K 31/555A61K 35/28A61K 31/496A61K 31/551C12N 5/0789A61K 31/4427A61K 35/12A61K 31/33
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Methods to mobilize progenitor/stem cells
- Applicant name
- Genzyme Corporation
- Opponent name
- Generics [UK] Limited (trading as Mylan)
Teva Pharmaceutical Industries Ltd.
Accord Healthcare Ltd
Sandoz AG
Zentiva, k.s.
STADA Arzneimittel AG
betapharm Arzneimittel GmbH - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 54(5)European Patent Convention Art 76(1)
- Keywords
- Divisional application - added subject-matter (yes)
Claim construction - Article 54(5) EPC applicable (no)
Novelty - novelty of claimed substance (no) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.